Life Sciences Tools and Services
Company Overview of Cancer Research Technology Limited
Cancer Research Technology Limited operates as a cancer-focused drug discovery, technology transfer, and commercialization company. It develops and licenses oncology related opportunities with pharmaceutical and biotechnology companies; and translates academic discoveries into industrial propositions. The company engages in sourcing and developing cancer discoveries; providing technology transfer services to cancer researchers; and identifying scientific and business solutions to unmet needs in cancer. Its drug discovery programs include the identification of small molecule inhibitors against various target classes, including kinases, kinesins, methyltransferases, and molecular chaperone tar...
407 St John Street
London, EC1V 4AD
Founded in 1982
Key Executives for Cancer Research Technology Limited
Chief Executive Officer and Director
Chief Operating Officer and Chief Executive of Cancer Research UK
Head of Medicinal Chemistry
Head of Molecular Pharmacology
Head of Clinical Partnerships
Compensation as of Fiscal Year 2013.
Cancer Research Technology Limited Key Developments
Cancer Research Technology Collaborates with Nuevolution
Nov 6 13
Cancer Research Technology, a commercial subsidiary of Cancer Research UK, has collaborated with Nuevolution, a Danish drug discovery company. The collaboration is aimed at discovering anti-cancer drug molecules targeting several key proteins. The transaction is intended to identify drug leads that block the activity of a number of cancer therapeutic targets, which could lead to the development of first-in-class novel treatments for cancer
patients. According to the deal, several diverse small molecules will be monitored using Nuevolution's proprietary Chemetics technology to identify drug candidate molecules that home in on selected targets. The deal will see Cancer Research Technology provide expert information about the biology of the targets through Cancer Research UK's network of scientists.
Cancer Research Technology Limited Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 09:00 AM
Oct 16 13
Cancer Research Technology Limited Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 09:00 AM. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria. Speakers: Keith Blundy, Chief Executive Officer and Director.
Cancer Research Technology Ltd. and Teva Pharmaceutical Industries Ltd. Form R&D Alliance for Cancer DNA Damage Response Drugs
Sep 16 13
Cancer Research Technology Ltd. (CRT) and Teva Pharmaceutical Industries Ltd. have signed a multi-project alliance agreement to research and develop first-in-class cancer drugs that modulate DNA damage and repair response (DDR) processes in cancer cells. DDR plays a key role in protecting cancer cells from the damaging effect of chemotherapy - creating an in-built antidote to the toxic effects of the anti-tumor drug. The alliance provides Teva with the opportunity to research and develop selected and differentiated novel treatments targeting DDR processes. With a focus on mechanisms and molecular targets related to the emergence of therapeutic resistance in cancer cells, the partnership also opens up the potential to expand the clinical utility and therapeutic effectiveness of Teva's current portfolio of oncology chemotherapeutic agents. This approach builds on Teva's growing focus on personalized medicine throughout its R&D pipeline, and specifically within its oncology portfolio. CRT and Teva will then jointly undertake chemical lead generation activities. Under the terms of the agreement, CRT will receive research funding and be eligible to receive milestone payments, and royalties on projects advancing through Teva's drug pipeline.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries